Literature DB >> 17751

Cyanoguanidine-thiourea equivalence in the development of the histamine H2-receptor antagonist, cimetidine.

G J Durant, J C Emmett, C R Ganellin, P D Miles, M E Parsons, H D Prain, G R White.   

Abstract

In the histamine H2-receptor antagonist metiamide (2a) isosteric replacement of thione sulfur (=S) by carbonyl oxygen (=O) or imino nitrogen (=NH) affords the urea 2c and guanidine 2d which are antagonists of decreased potency. The guanidine is very basic and at physiological pH is completely protonated. However, introduction of strongly electronegative substituents into the guanidine group reduces basicity and gives potent H2-receptor antagonists, viz. the cyanoguanidine 2b (cimetidine, "Tagamet") and nitroguanidine 2e. A correspondence between the activity of thioureas and cyanoguanidines is demonstrated for a series of structures 1-4. The close correspondence between cyanoguanidine and thiourea in many physicochemical properties and the pharmacological equivalence of these groups in H2-receptor antagonists leads to the description of cyanoguanidine and thiourea as bioisosteres. Acid hydrolysis of the cyanoguanidine 2b yields the carbamoylguanidine 2f at ambient temperatures and the guanidine 2d at elevated temperatures. Cimetidine is slightly more active than metiamide in vivo as an inhibitor of histamine-stimulated gastric acid secretion and has clinical use in the treatment of peptic ulcer and associated gastrointestinal disorders.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 17751     DOI: 10.1021/jm00217a007

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  14 in total

1.  Personal reflections on Sir James Black (1924-2010) and histamine.

Authors:  C Robin Ganellin
Journal:  Inflamm Res       Date:  2010-10-27       Impact factor: 4.575

2.  Tales from the war on error: the art and science of curating QSAR data.

Authors:  Marvin Waldman; Robert Fraczkiewicz; Robert D Clark
Journal:  J Comput Aided Mol Des       Date:  2015-08-20       Impact factor: 3.686

3.  Analysis of competitive antagonism when this property occurs as part of a pharmacological resultant.

Authors:  J W Black; V P Gerskowitch; P Leff; N P Shankley
Journal:  Br J Pharmacol       Date:  1986-11       Impact factor: 8.739

4.  Structural requirements of imidazole compounds to be inhibitors or activators of histamine methyltransferase: investigation of histamine analogues and H2-receptor antagonists.

Authors:  H Barth; W Lorenz
Journal:  Agents Actions       Date:  1978-06

5.  Proceedings of the British Pharmacological Society. Bath, 9th-11th April 1986. Abstracts.

Authors: 
Journal:  Br J Pharmacol       Date:  1986-06       Impact factor: 8.739

6.  Synthesis of Cyclic Guanidines Bearing N-Arylsulfonyl and N-Cyano Protecting Groups via Pd-Catalyzed Alkene Carboamination Reactions.

Authors:  Luke J Peterson; Jingyi Luo; John P Wolfe
Journal:  Org Lett       Date:  2017-05-23       Impact factor: 6.005

7.  Determination of submicrogram quantities of cimetidine and its biotransformation and degradation products.

Authors:  B Jenko; A Kosak; D Milivojevic; B Kralj
Journal:  Agents Actions       Date:  1983-04

8.  Inhibition of cortical acetylcholine release and cognitive performance by histamine H3 receptor activation in rats.

Authors:  P Blandina; M Giorgetti; L Bartolini; M Cecchi; H Timmerman; R Leurs; G Pepeu; M G Giovannini
Journal:  Br J Pharmacol       Date:  1996-12       Impact factor: 8.739

9.  Cimetidine and ranitidine: their interaction with human and pig liver microsomes and with purified cytochrome P-450.

Authors:  S Rendić; H H Ruf; P Weber; F Kajfez
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1984 Jul-Sep       Impact factor: 2.441

Review 10.  Recent advances in urea- and thiourea-containing compounds: focus on innovative approaches in medicinal chemistry and organic synthesis.

Authors:  Riccardo Ronchetti; Giada Moroni; Andrea Carotti; Antimo Gioiello; Emidio Camaioni
Journal:  RSC Med Chem       Date:  2021-05-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.